These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 30448307

  • 1. Predicted amorphous solubility and dissolution rate advantages following moisture sorption: Case studies of indomethacin and felodipine.
    Skrdla PJ, Floyd PD, Dell'Orco PC.
    Int J Pharm; 2019 Jan 30; 555():100-108. PubMed ID: 30448307
    [Abstract] [Full Text] [Related]

  • 2. Practical Estimation of Amorphous Solubility Enhancement Using Thermoanalytical Data: Determination of the Amorphous/Crystalline Solubility Ratio for Pure Indomethacin and Felodipine.
    Skrdla PJ, Floyd PD, Dell'orco PC.
    J Pharm Sci; 2016 Sep 30; 105(9):2625-2630. PubMed ID: 27372548
    [Abstract] [Full Text] [Related]

  • 3. Solubility Advantage (and Disadvantage) of Pharmaceutical Amorphous Solid Dispersions.
    Huang S, Mao C, Williams RO, Yang CY.
    J Pharm Sci; 2016 Dec 30; 105(12):3549-3561. PubMed ID: 27692620
    [Abstract] [Full Text] [Related]

  • 4. Recrystallization of nifedipine and felodipine from amorphous molecular level solid dispersions containing poly(vinylpyrrolidone) and sorbed water.
    Marsac PJ, Konno H, Rumondor AC, Taylor LS.
    Pharm Res; 2008 Mar 30; 25(3):647-56. PubMed ID: 17846870
    [Abstract] [Full Text] [Related]

  • 5. Predicting the solubility enhancement of amorphous drugs and related phenomena using basic thermodynamic principles and semi-empirical kinetic models.
    Skrdla PJ, Floyd PD, Dell'Orco PC.
    Int J Pharm; 2019 Aug 15; 567():118465. PubMed ID: 31279056
    [Abstract] [Full Text] [Related]

  • 6. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis.
    Murdande SB, Pikal MJ, Shanker RM, Bogner RH.
    J Pharm Sci; 2010 Mar 15; 99(3):1254-64. PubMed ID: 19697391
    [Abstract] [Full Text] [Related]

  • 7. Mutual Impact of Phase Separation/Crystallization and Water Sorption in Amorphous Solid Dispersions.
    Luebbert C, Wessner M, Sadowski G.
    Mol Pharm; 2018 Feb 05; 15(2):669-678. PubMed ID: 29309155
    [Abstract] [Full Text] [Related]

  • 8. Ability of different polymers to inhibit the crystallization of amorphous felodipine in the presence of moisture.
    Konno H, Taylor LS.
    Pharm Res; 2008 Apr 05; 25(4):969-78. PubMed ID: 17520180
    [Abstract] [Full Text] [Related]

  • 9. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen.
    Löbmann K, Laitinen R, Grohganz H, Gordon KC, Strachan C, Rades T.
    Mol Pharm; 2011 Oct 03; 8(5):1919-28. PubMed ID: 21815614
    [Abstract] [Full Text] [Related]

  • 10. A New Method of Constructing a Drug-Polymer Temperature-Composition Phase Diagram Using Hot-Melt Extrusion.
    Tian Y, Jones DS, Donnelly C, Brannigan T, Li S, Andrews GP.
    Mol Pharm; 2018 Apr 02; 15(4):1379-1391. PubMed ID: 29205040
    [Abstract] [Full Text] [Related]

  • 11. Understanding the behavior of amorphous pharmaceutical systems during dissolution.
    Alonzo DE, Zhang GG, Zhou D, Gao Y, Taylor LS.
    Pharm Res; 2010 Apr 02; 27(4):608-18. PubMed ID: 20151181
    [Abstract] [Full Text] [Related]

  • 12. Preparation and characterization of co-amorphous Ritonavir-Indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions.
    Dengale SJ, Ranjan OP, Hussen SS, Krishna BS, Musmade PB, Gautham Shenoy G, Bhat K.
    Eur J Pharm Sci; 2014 Oct 01; 62():57-64. PubMed ID: 24878386
    [Abstract] [Full Text] [Related]

  • 13. Solubility of crystalline organic compounds in high and low molecular weight amorphous matrices above and below the glass transition by zero enthalpy extrapolation.
    Amharar Y, Curtin V, Gallagher KH, Healy AM.
    Int J Pharm; 2014 Sep 10; 472(1-2):241-7. PubMed ID: 24968139
    [Abstract] [Full Text] [Related]

  • 14. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH, Gordon S, Holm R, Selen A, Rades T, Müllertz A.
    Eur J Pharm Biopharm; 2013 Nov 10; 85(3 Pt B):942-51. PubMed ID: 24075980
    [Abstract] [Full Text] [Related]

  • 15. An investigation into the role of polymeric carriers on crystal growth within amorphous solid dispersion systems.
    Tian Y, Jones DS, Andrews GP.
    Mol Pharm; 2015 Apr 06; 12(4):1180-92. PubMed ID: 25692314
    [Abstract] [Full Text] [Related]

  • 16. Real time Raman imaging to understand dissolution performance of amorphous solid dispersions.
    Tres F, Treacher K, Booth J, Hughes LP, Wren SA, Aylott JW, Burley JC.
    J Control Release; 2014 Aug 28; 188():53-60. PubMed ID: 24910191
    [Abstract] [Full Text] [Related]

  • 17. Moisture-induced phase separation and recrystallization in amorphous solid dispersions.
    Luebbert C, Sadowski G.
    Int J Pharm; 2017 Oct 30; 532(1):635-646. PubMed ID: 28867448
    [Abstract] [Full Text] [Related]

  • 18. In situ amorphisation of indomethacin with Eudragit® E during dissolution.
    Priemel PA, Laitinen R, Grohganz H, Rades T, Strachan CJ.
    Eur J Pharm Biopharm; 2013 Nov 30; 85(3 Pt B):1259-65. PubMed ID: 24056054
    [Abstract] [Full Text] [Related]

  • 19. Dissolution and precipitation behavior of amorphous solid dispersions.
    Alonzo DE, Gao Y, Zhou D, Mo H, Zhang GGZ, Taylor LS.
    J Pharm Sci; 2011 Aug 30; 100(8):3316-3331. PubMed ID: 21607951
    [Abstract] [Full Text] [Related]

  • 20. Comparative Study of Different Methods for the Prediction of Drug-Polymer Solubility.
    Knopp MM, Tajber L, Tian Y, Olesen NE, Jones DS, Kozyra A, Löbmann K, Paluch K, Brennan CM, Holm R, Healy AM, Andrews GP, Rades T.
    Mol Pharm; 2015 Sep 08; 12(9):3408-19. PubMed ID: 26214347
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.